Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate AP026 (TQA2226) for Injection in Adult Subjects After Single/Multiple Administration.
NCT06143423 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate AP026 (TQA2226) for Injection in Adult Subjects After Single/Multiple Administration.
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- May 24, 2023
- Completion date
- March 16, 2026
- Enrollment
- 14 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.